{"nctId":"NCT01146418","briefTitle":"Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)","startDateStruct":{"date":"2010-06-02","type":"ACTUAL"},"conditions":["Infertility"],"count":307,"armGroups":[{"label":"Corifollitropin alfa 150 μg","type":"EXPERIMENTAL","interventionNames":["Biological: Corifollitropin alfa"]},{"label":"recFSH 300 IU","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: recFSH (follitropin beta)"]}],"interventions":[{"name":"Corifollitropin alfa","otherNames":[]},{"name":"recFSH (follitropin beta)","otherNames":["Follistim® AQ Cartridge"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant must have provided written informed consent for the trial.\n* Participant must have cryopreserved embryo(s) in trial P06029 (NCT01144416) of which at least one embryo is thawed for use in a subsequent FTET cycle.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"35 Years","maximumAge":"42 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With ≥1 Vital Pregnancy (Cumulative Vital Pregnancy Rate)","description":"The cumulative vital pregnancy rate was defined as the number of participants with at least 1 vital pregnancy in a controlled ovarian stimulation (COS) cycle in Base Study P06029 or a frozen-thawed embryo transfer (FTET) in Follow Up Study P06031, divided by the total number of participants in each Full Analysis Set (FAS) treatment group. A vital pregnancy was defined as an intrauterine pregnancy with fetal heart tones assessed at least 35 days (≥5 weeks) after embryo transfer (ET).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":null},{"groupId":"OG001","value":"33.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥1 Live Birth (Cumulative Live-Birth Rate)","description":"The cumulative live-birth rate was defined as the number of participants with at least 1 live birth after ET in a COS cycle in Base Study P06029 or an FTET in Follow-Up Study P06031, divided by the total number of participants in each FAS treatment group.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.2","spread":null},{"groupId":"OG001","value":"29.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":151},"commonTop":["Abortion spontaneous","Vomiting in pregnancy","Haemorrhage in pregnancy","Headache","Abortion missed"]}}}